Therapeutic news in ALS.

Area of Science:

• Neuroscience
• Neurology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron loss, leading to progressive weakness and amyotrophy.
• Current treatments like riluzole and edaravone offer limited benefits, with a median survival of approximately 36 months.
• The heterogeneity of ALS pathophysiology and clinical features presents significant challenges for drug development.

Purpose of the Study:

• To review current and developing treatment options for Amyotrophic Lateral Sclerosis (ALS).
• To highlight the diverse range of therapeutic strategies under investigation for ALS.
• To emphasize the urgent need for more effective ALS therapies.

Main Methods:

• Comprehensive review of existing literature on ALS treatments.
• Analysis of therapeutic approaches, including repurposed drugs, biotechnology, and gene therapy.
• Examination of challenges in clinical trials for ALS drug development.

Main Results:

• Despite extensive research over 30 years, no curative drug for ALS has been found.
• Existing treatments provide only marginal improvements in survival and disease progression.
• A wide array of novel therapeutic strategies are currently being explored.

Conclusions:

• There is a critical unmet need for effective treatments to significantly improve ALS progression and patient outcomes.
• Innovative approaches such as biotechnology and gene therapy hold promise for future ALS treatment.
• Addressing the heterogeneity of ALS is crucial for successful therapeutic development.